Christopher John Jaeger

US Patent:

20070208166, Sep 6, 2007

Filed:

Oct 22, 2004

Appl. No.:

10/576932

Inventors:

Deborah Baly - Lafayette CA, US
Adam Galan - Alameda CA, US
Mohamed Ibrahim - Mountain View CA, US
Christopher Jaeger - Brisbane CA, US
Patrick Kearney - San Francisco CA, US
James Leahy - San Leandro CA, US
Gary Lewis - San Francisco CA, US
Kirk McMillan - Burlingame CA, US
Robin Noguchi - San Bruno CA, US
John Nuss - Danville CA, US
Jason Parks - Sacramento CA, US
Kevin Schnepp - Elk Grove CA, US
Xian Shi - San Bruno CA, US
Matthew Williams - San Mateo CA, US
Wei Xu - Danville CA, US
Wentao Zhang - Foster City CA, US

Assignee:

Exelixis, Inc. - South San Franciso CA

International Classification:

C07D 471/02

US Classification:

534766000, 564152000, 546336000, 548492000, 546118000, 546272400, 548495000, 548537000, 544250000, 544333000, 544284000, 548161000, 544278000, 544360000, 540496000, 546167000, 564050000, 546146000, 548470000, 549362000, 544386000, 548215000, 548364100, 546229000, 548190000, 546114000

Abstract:

The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.